Asia Pacific Point-of-Care Diagnostic Market is expected to reach US$ 16,188.31 Million by 2028

PRESS RELEASE BY The Insight Partners 30 Nov 2021

Share this press on

Infectious Disease Segment to Register Highest CAGR During 2021–2028

According to our new market research study on “Asia Pacific Point-of-Care Diagnostic Market Forecast to 2028 –COVID-19 Impact and Analysis and Forecast – by Application and End User,” the market is expected to reach US$ 16,188.31 million by 2028 from US$ 6,799.86 million in 2021; it is estimated to grow at a CAGR of 13.2% from 2021 to 2028. The report highlights trends prevailing in the market and drivers and hindrances pertaining to the market growth.       

Based on application, the Asia Pacific point-of-care diagnostic market is segmented into infectious diseases, cardiac markers, oncology markers, OTC diagnostic tests, drugs of abuse, blood gas testing, fertility testing, urinalysis, coagulation, hematology, glucose monitoring, ambulatory chemistry, decentralized clinical chemistry, and other application. The glucose monitoring segment accounted for the largest market share in 2021, and the infectious disease segment is anticipated to register the highest CAGR during the forecast period.

Based on end user, the Asia Pacific point-of-care diagnostic market is segmented into professional diagnostic centers, home care, research laboratories, and other end-users. The research laboratories segment held the largest share of the market in 2021, and the home care segment is estimated to register the highest CAGR in the market during the forecast period.   

The COVID-19 outbreak has created an extraordinary emergency that significantly affected the supply chain. The supply chain disruptions, along with the enormous demand for effective therapies for the COVID-19 treatment, have put the healthcare research industry in a critical situation globally. The COVID-19 pandemic has accelerated the point-of-care diagnostics market, as companies are developing point-of-care devices to provide a rapid and reliable method for virus detection. Due to the pandemic, the demand for these devices has escalated, and manufacturing companies are competing to make the fast, easy, and reliable next-generation POC platforms.     

F. Hoffmann-La Roche Ltd.; Danaher Corporation; Bio-Rad Laboratories, Inc.; Abbott Laboratories; Siemens AG; Becton; Dickinson and Company; Nova Biomedical Corporation; Talis Biomedical Corporation; Quidel Corporation; and Chembio Diagnostics, Inc. are among the leading companies operating in the Asia Pacific point-of-care diagnostic market.    

Contact Us
Phone: +1-646-491-9876
Email Id:

Download Free PDF Brochure